Hantz Financial Services Inc. Sells 5,965 Shares of Penumbra, Inc. $PEN

Hantz Financial Services Inc. decreased its position in shares of Penumbra, Inc. (NYSE:PEN) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,145 shares of the company’s stock after selling 5,965 shares during the quarter. Hantz Financial Services Inc. owned 0.08% of Penumbra worth $9,683,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Simplify Asset Management Inc. lifted its position in Penumbra by 89.7% during the fourth quarter. Simplify Asset Management Inc. now owns 15,827 shares of the company’s stock worth $4,921,000 after purchasing an additional 7,485 shares during the period. William Blair Investment Management LLC bought a new stake in Penumbra during the fourth quarter worth about $107,567,000. Prospera Financial Services Inc lifted its position in Penumbra by 12.6% during the fourth quarter. Prospera Financial Services Inc now owns 2,841 shares of the company’s stock worth $883,000 after purchasing an additional 318 shares during the period. Coldstream Capital Management Inc. lifted its position in Penumbra by 6.0% during the fourth quarter. Coldstream Capital Management Inc. now owns 843 shares of the company’s stock worth $262,000 after purchasing an additional 48 shares during the period. Finally, Leonteq Securities AG acquired a new position in Penumbra during the fourth quarter worth about $155,000. Institutional investors own 88.88% of the company’s stock.

Insider Activity at Penumbra

In related news, CFO Maggie Yuen sold 2,432 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $342.30, for a total value of $832,473.60. Following the sale, the chief financial officer directly owned 18,353 shares in the company, valued at $6,282,231.90. This represents a 11.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director owned 8,719 shares in the company, valued at $2,861,750.18. The trade was a 1.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on PEN shares. Evercore reissued an “outperform” rating and set a $335.00 target price on shares of Penumbra in a research note on Thursday, May 7th. UBS Group reissued a “neutral” rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, February 26th. Citigroup lowered their target price on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen raised Penumbra to a “hold” rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat, Penumbra has a consensus rating of “Hold” and a consensus target price of $361.33.

Penumbra Stock Performance

Penumbra stock opened at $328.46 on Monday. The business has a 50 day moving average of $329.87 and a 200-day moving average of $322.45. Penumbra, Inc. has a 1 year low of $221.26 and a 1 year high of $362.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The company has a market capitalization of $12.92 billion, a P/E ratio of 75.68, a P/E/G ratio of 2.01 and a beta of 0.74.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The firm had revenue of $374.76 million during the quarter, compared to analyst estimates of $370.47 million. During the same period in the prior year, the company earned $0.83 EPS. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, equities research analysts predict that Penumbra, Inc. will post 5.08 earnings per share for the current year.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.